Thus, for three out of four enhancers in our CLL‐specific gene regulatory network, a predicted loss of EBF1 binding in CLL was experimentally validated by the EBF1 ChIP‐seq. The gene discussed is EBF1; the disease is B-cell chronic lymphocytic leukemia.